Sarepta Therapeutics falls in sympathy with Novartis trial failure
-6.93% to $20.94 from $22.50
What moved SRPT
- Sarepta Therapeutics shares fell as much as 15.5% after Novartis’ del-desiran missed the primary endpoint of its Phase III HARBOR trial in myotonic dystrophy type 1.
- The move was described as a sector-wide reaction, with the trial failure rattling investor confidence across the broader neuromuscular-disease therapeutic class rather than reflecting new Sarepta-specific news.
Sources: Seeking Alpha · Investing.com